Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at Craig Hallum

Craig Hallum began coverage on shares of Opus Genetics (NASDAQ:IRD) in a research report released on Friday morning, Marketbeat reports. The brokerage issued a buy rating and a $6.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Opus Genetics in a research report on Tuesday, April 1st. Jones Trading reduced their price objective on shares of Opus Genetics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st.

Opus Genetics Stock Down 0.7 %

NASDAQ IRD opened at $0.71 on Friday. Opus Genetics has a 52 week low of $0.65 and a 52 week high of $1.56. The business’s 50 day moving average price is $1.01. The firm has a market cap of $32.23 million, a PE ratio of -0.65 and a beta of 0.11.

Opus Genetics (NASDAQ:IRD) last posted its earnings results on Monday, March 31st. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.93). Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The business had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $11.10 million. Sell-side analysts predict that Opus Genetics will post -1.22 earnings per share for the current year.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.